Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
Immix Biopharma, Inc. (Nasdaq:IMMX)
Format
JPEG
Source
Immix Biopharma, Inc.